The Zeiss Group’s Medical Technology segment, as well as its the Vision Care unit, has been announced as a major contributor to the group’s record-breaking financial success over the last year.
Announcing the results of its 2018/19 fiscal year, which ended in September, the organisation revealed revenue had grown 11% over the previous year to reach €6.43 billion (AU$10.4 b). Revenue rose by 8% when adjusted for currency and acquisition effects. Earnings before interest and taxes also posted a significant increase, reaching €1.06 billion (AU$1.72 b) from €772 million (AU$1.25 b) the previous year.
Notably, the results mark the tenth consecutive year of record-breaking financial success for the company.
All four of Zeiss’ segments posted an increase in revenue for the year, however the greatest change was seen in its Medical Technology segment. The company said this was due to greater demand for both microsurgery and ophthalmology solutions.
Zeiss’ Vision Care business unit, which is part of the company’s Consumer Markets segment, was also singled out for its above-market growth and revenue for the first time surpassing the €1 billion (AU$1.6 billion) mark.
“All Zeiss segments have developed extremely well,” Dr Michael Kaschke, Zeiss group president and CEO, said.
“This is quite remarkable, especially in the midst of an uncertain economic climate and profound structural change in different industries. Zeiss has consistently prepared for these scenarios and is well-positioned for the future as well as resilient thanks to its corporate strategy, the Zeiss Agenda 2020. Moreover, as a global technology leader, Zeiss is on its way in many segments and areas to becoming a shaper in its markets.”
